Navigation Links
Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
Date:11/19/2012

nsisted primarily of amortization of upfront payments received from GSK and Sanofi which we amortize monthly on a straight-line basis over our period of performance. The total amortization attributable to payments from Sanofi was $2.5 million and $7.5 million for each of the three and nine months ended September 30, 2012 and 2011, respectively.  The total amortization attributable to upfront payments from GSK was $186,000 and $1.3 million for the three months ended September 30, 2012 and 2011, respectively, and $1.8 million and $2.9 million for the nine months ended September 30, 2012 and 2011, respectively.  The decrease in the amount amortized for GSK in 2012 compared to 2011 is the result of our June 2012 amendment to the collaboration agreement which extended our period of performance.

Research and Development ExpensesResearch and development expenses were $5.2 million and $14.7 million for the three and nine months ended September 30, 2012, respectively, compared to $3.9 million and $12.8 million for the same periods in 2011. The increase of $1.4 million and $1.9 million for the three and nine month periods ended September 30, 2012 was primarily related to increases in payroll and related benefits, laboratory supplies and external services to advance our preclinical programs.

General and Administrative ExpensesGeneral and administrative expenses were $1.1 million and $3.0 million for the three and nine months ended September 30, 2012, respectively, compared to $907,000 and $2.9 million for the same periods in 2011. The increases primarily represent legal services related to our transactions with AZ and Biogen Idec completed in August 2012.

Conference Call & Webcast InformationRegulus will host a conference call and webcast at 5:00 pm Eastern Standard Time today to discuss its third quarter 2012 financial results and highlights. A live w
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
2. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
3. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
4. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
5. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
6. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
7. Grupo Casa Saba Reports - Grupo Casa Saba Announces its Intention to Delist From the New York Stock Exchange
8. Solos Endoscopy Reports Book Value of $2,393,522 for Period Ended September 30, 2012
9. ULURU Inc. Reports Third Quarter 2012 Financial Results
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
11. China Pharma Holdings, Inc. Reports Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Reductions in kidney ... years in people with diabetes type 2 ... benefits for the kidneys." Australian researchers have ... 2 diabetes leads to persistent reductions in kidney failure ... The global study has found that, five and a ...
(Date:9/18/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the ... Market 2014-2018" report to their offering. ... Cytogenetics involves the study of chromosomes using ... functions of genes and chromosomes. It plays ...
(Date:9/18/2014)... , Sept. 18, 2014  Aratana Therapeutics, ... therapeutics company focused on licensing, developing and commercializing ... the full exercise of the underwriters, option to ... connection with the company,s previously announced public offering ... the shares are being offered by Aratana Therapeutics.  ...
Breaking Medicine Technology:ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... Response or Reduction of,Lesion Size by More than ... 2007 /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation today announced the ... the safety and,efficacy of pilot process HspE7, an ... women,with the highest grade of cervical dysplasia (CIN ...
... WIRE)--Mar 7, 2007 - BioLineRx Ltd.,(TASE:BLRX), Israel's ... from trials of BL-1040 demonstrating that,BL-1040 is ... a myocardial infarction (MI), thereby reducing left ... pig model. Professor,Jonathan Leor, MD, Director of ...
Cached Medicine Technology:Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 2Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 3Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 5Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 6BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 2BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 3
(Date:9/19/2014)... Research & Road Safety - Queensland (CARRS-Q) study have ... (OSIT) which is being held on the Gold Coast ... road safety researcher, said speed limit credibility was being ... traffic controls remained in place at inactive roadwork sites. ... asked to slow down at roadwork sites but find ...
(Date:9/19/2014)... researchers showed monkeys a number of images representing ... of 39 neurons by using microelectrodes. They found ... intensities of the responses linearly according to either ... This shows that these 3 perceptual parameters are ... variety of glosses. They also found that different ...
(Date:9/19/2014)... The Canton Group, Baltimore’s leading web development firm, has ... Xaverian Brothers. The new site aligns the Catholic order of ... another through a life of Gospel witness lived in community ... care and compassionate love to the people of the world ... responsive web design, which allows users to easily access information ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 Ticket ... Wonder tickets for his 2014 concert tour. Concertgoers ... the music business, there are a handful of artists that ... Wonder. Born in Saginaw, MichIgan, Wonder has been a force ... his time in the music business, he has released 23 ...
(Date:9/19/2014)... September 19, 2014 Lifeinsuranceover50s.biz as released ... who have heart disorders can still qualify for life ... qualify for life insurance plans that do not require ... be purchased online, in just a few minutes. ... also be purchased by clients who have health problems, ...
Breaking Medicine News(10 mins):Health News:Don't cry wolf: Drivers fed up with slowing down at inactive roadwork sites 2Health News:Neurons express 'gloss' using three perceptual parameters 2Health News:Xaverian Brothers Partner with The Canton Group to Launch New Website 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 3Health News:No Medical Exam Life Insurance For Clients Who Have Heart Problems! 2
... bitten by a bat and subsequently diagnosed with rabies has been ... is being offered, the chances of the boy recovering is very ... of Humble High School fell ill last week, unaware of the ... could happen, a bat had flown into his house while he ...
... study conducted by a team at Queeen's has suggested ... when hooked up to dialysis// yield better results in ... ,This five-month, exercise intervention study of dialysis patients ... King-VanVlack, member of the Cardiac, Circulation and Respiratory (CCR) ...
... that more than 80 million American adults are smokers, obese or ... and an early death. // ,Data from a ... of adults in the United States who have one or both ... categories is about 9 million people and this would include a ...
... study states that the organ donation rate in UK is ... relatives are reluctant to allow such procedures. // This was ... potential organ donors because they are distressed and confused about ... ,The UK Transplant, which carried out a two-year audit, ...
... the Japanese Encephalitis immunization drive has not gone down well ... have taken place on June 18, but the government has ... delivery of 5.2 million doses of the Japanese Encephalitis tissue ... , ,The remaining 13.5 million doses are expected to ...
... to place on record the exemplary work of art by students ... effort by Oman in the ‘Unite for children Unite against Aids’ ... ‘Unite for Children Unite Against Aids’ campaign encompasses four major goals ... the percentage of the young victims of HIV/Aids; to provide better ...
Cached Medicine News:Health News:Exercise Combined with Dialysis Yields Better Results 2Health News:Grieving Relatives Reluctant To Give Consent For Organ Donation 2
Nitinol Flat Wire Basket...
1.5 Fr Nitinol Tipless Stone Basket...
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
Medicine Products: